MarketsandMarkets

ImmunoBio Series 2024 - UK Edition

07th - 8th March 2024

Park Plaza Victoria London by Radisson, 239 Vauxhall Bridge Rd, Pimlico, London SW1V 1EQ, UK

Bridging Science, Innovation, and Health for a Better Tomorrow

MarketsandMarkets presents the Immunobio Series, an extraordinary set of conferences taking place on 7-8 March 2024 in London, UK.

MarketsandMarkets 5th Annual Biomarker and Companion Diagnostics Conference:

Dive into the world of biomarkers at our flagship event, uniting experts and industry leaders to drive innovation in healthcare, diagnostics, and personalized medicine. Explore groundbreaking research and applications, fostering collaboration and knowledge sharing. This conference will convene experts, researchers, scientists, academicians, and industry leaders from across the USA to drive innovation and collaboration. Esteemed keynote speakers will provide groundbreaking insights into the latest developments and future prospects of biomarker research. This annual event is served as a hub for knowledge sharing, collaboration, and exploration of the latest developments in biomarker research and applications.

MarketsandMarkets 8th Annual Next Gen Immuno-Oncology Conference:

Explore the forefront of cancer treatment at our flagship Immuno-Oncology Conference. Keynote presentations, Brainstorming Panel Discussions and Case studies will give the stakeholders an opportunity to discuss and understand the issues faced and come up with solutions. With more than 40 speakers across the world from pharma, biopharma and biotech companies, the congress will discuss the latest updates and share insights in development of ADC’s, Monoclonal Antibodies, Bispecific Antibodies, Immune Checkpoint Inhibitors and Cellular Therapy shaping the future of immuno-oncology.

Join us for this transformative event, where innovation meets collaboration, shaping the future of healthcare and biotechnology.

CO-LOCATED CONFERENCES

8th Annual MarketsandMarkets Next-Gen Immuno-Oncology Conference
5th Annual MarketsandMarkets Biomarker and Companion Diagnostics Conference

WHAT TO EXPECT

  1. Cutting-Edge Insights: Access the latest advancements in biomarker discovery, precision medicine, and clinical applications spanning cancer, immunology, neurodegenerative disorders, and cardiovascular biomarkers.
  2. Innovative Immunotherapy: Dive into immune-oncology projects, exploring antibodies, cellular therapy, and immune checkpoint research. Contribute to interactive discussions, share your work, and stay updated on cutting-edge technologies and platforms.
  3. Networking and Collaboration: Connect with industry leaders, researchers, and peers. Foster collaborations, engage in thought-provoking discussions, and explore partnership opportunities.
  4. Professional Development: Enhance your skills with workshops on biomarker data analysis, machine learning, and artificial intelligence applications. Learn best practices and methodologies for biomarker and IO research.
  5. Practical Applications: Discover how research translates into real-world applications. Explore exhibitor showcases, demonstrations, and case studies, gaining insights into the latest tools and technologies.
  6. Personal and Industry Growth: Step out of your comfort zone, engage in interactive roundtables, and contribute to key discussions. Elevate your personal and professional growth within the dynamic fields of biomarker research and immunotherapy.

Immerse yourself in groundbreaking research, expand your network, and drive innovation at the Immunobio Series, where science meets collaboration.

Steam A - Biomarker and Companion Diagnostics Conference

Stream B & C- Next Gen Immuno-Oncology Conference

  1. Biomarker Discovery: Discussions on novel techniques and strategies for identifying new biomarkers, including genomics, proteomics, metabolomics, and bioinformatics.
  2. Precision Medicine: The role of biomarkers in tailoring treatments to individual patients for better efficacy and reduced side effects.
  3. Clinical Validation and Validation Strategies: Strategies for rigorously validating biomarkers for clinical use and addressing challenges in biomarker validation.
  4. Clinical Applications of Biomarker: Cancer, Immunology, Neurodegenerative Disorders, Cardiovascular Biomarkers
  5. Bioinformatics and Data Analysis: Workshops and sessions on the analysis of biomarker data, including machine learning and artificial intelligence approaches.
  6. Biomarker-Based Diagnostics: Presentations on the development and commercialization of biomarker-based diagnostic tests and platforms.
  7. Collaborations and Industry Partnerships: Sessions on fostering collaboration between academia, industry, and government agencies to advance biomarker research.

 

  1. Preclinical and Translational Immuno-Oncology Developments
  2. Next Gen Antibodies and Targeted Therapies
  3. Immune Checkpoint Inhibitors and Combination Therapies
  4. Tumor Microenvironment and Cancer Biomarkers
  5. CAR-T cell therapy, T Cell Therapy, Adoptive Cell Therapy
  6. Cancer Vaccines and Cancer Microbiome
  7. Personalizing Cancer Treatment- Challenges and Opportunities

 

CONFERENCE AGENDA

Registration

08:15 - 08:50

Welcome note from MarketsandMarkets

08:50 - 08:55

Opening Remarks from the Chairperson

08:55 - 09:00

BIOMARKER DRUG DISCOVERY AND ASSAY VALIDATION

Keynote Presentation - ICT01, an anti-BTN3A mAb activating Vg9Vd2 cells

Emmanuel Valentin

Emmanuel Valentin, Vice President, Translational Medicine, Imcheck Therapeutics

09:00 - 09:30

Biomarker assay development and validation for cancer treatment

Nathalie Steinhoff

Nathalie Steinhoff, Scientist, Cancer Immunotherapy, Numab Therapeutics AG

09:30 - 10:00

Enhanced Biomarker Discovery and Validation Using TMT® Proteomics

Ian Pike

Ian Pike, Chief Scientific Officer, Proteome Sciences PLC

10:00 - 10:30

Morning Refreshments and Poster Presentation | One-to-One Networking Meetings

10:30 - 11:15

Transforming Oncology with Predicine’s Liquid Biopsy Solutions

Shidong Jia

Shidong Jia, Founder, CEO, Predicine

11:15 - 11:45

Combination Strategies for Personalised Cancer Therapy

Sreejith Raveendran

Sreejith Raveendran, Assistant Professor, Teesside University

11:45 - 12:15

Sample quality strategies, operations and patient centricity for biomarker analysis

Debora Souza Da Costa

Debora Souza Da Costa, Senior Biosample Project Leader., Roche

12:15 - 12:45

Comprehensive Biomarker Strategies To Decipher The Tumor Microenvironment: From Tissue To High-Quality Spatial Insights

Angela Vasaturo

Angela Vasaturo , Senior Field Application Scientist , Ultivue, UK

12:45 - 13:15

Lunch and Poster Presentation | One-to-One Networking Meetings

13:15 - 14:15

ROLE OF BIOMARKERS IN PERSONALIZED MEDICINE

AI-driven analysis of morphological biomarkers for trials in haemato-oncology

Daniel Royston

Daniel Royston, Consultant Clinical Advisor, Ground Truth Labs

14:15 - 14:45

AI in medicine - A paradigm shift for the diagnostic industry

Thomas Gohl

Thomas Gohl, Market Development Manager, Roche Diagnostics

14:45 - 15:15

Development of a colorectal cancer methylation panel and an actionable cancer mutation panel using targeted bisulfite next-generation sequencing

Collin Hidzik

Collin Hidzik, Scientist in product and business development , EpigenDx

15:15 - 15:45

Afternoon Refreshments and Poster Presentation | One-to-One Networking Meetings

15:45 - 16:30

Lifestyle and epigenetic changes

Aparna Duggirala

Aparna Duggirala, Lecturer, Clinical Genetics, University of Derby

16:30 - 17:00

Back translation of preclinical models to humans

Maria Dermit

Maria Dermit, Computational Biologist, Novo Nordisk Research Centre Oxford

17:00 - 17:30

Closing Remarks from the Chairperson

17:30 - 17:30

Drinks Reception & Networking

17:30 - 17:30

End of Day 1

17:30 - 17:35

Registration

08:15 - 08:50

Welcome note from MarketsandMarkets

08:50 - 08:55

Opening Remarks from the Chairperson

08:55 - 09:00

NEW ANTIBODIES DEVELOPMENTS AND UPDATES

Keynote Presentation- HLA-agnostic T-cell recognition of cancer

Andrew Sewell

Andrew Sewell , Distinguished Research Professor and Wellcome Trust Senior Investigator,, Cardiff University

09:00 - 09:30

IgE Immunotherapy from Concept to Translation

Sophia Karagiannis

Sophia Karagiannis, Professor, Translational Cancer Immunology and Immunotherapy, Kings College London, UK

09:30 - 10:00

Investigating PD-L1 expression in Circulating Tumor Cells of metastatic cancer patients, using Parsortix® system.

Anne-Sophie Pailhes-Jimenez

Anne-Sophie Pailhes-Jimenez, R&D Director, ANGLE Europe Limited

10:00 - 10:30

Morning Refreshments and Poster Presentation | One-to-One Networking Meetings

10:30 - 11:15

Targeting myeloid cells to augment antibody immunotherapy

Ali Roghanian

Ali Roghanian, PhD, FHEA | Associate Prof in Cancer Immunotherapy | BM Research Project Deputy Module Leader, Centre for Cancer Immunology | Faculty of Medicine | University of Southampton

11:15 - 11:45

From Biomarker Discovery to Diagnostic: Navigating the Translational Journey

Valerie Balme

Valerie Balme, Associate Director, Business Development, Biopharma

11:45 - 12:15

Fc Engineering to overcome suppressive tumour microenvironments

Stephen Beers

Stephen Beers, Professor, Immunology and Immunotherapy, University of Southampton

12:15 - 12:45

Preclinical mouse models for I/O research

Jianming Xu

Jianming Xu, Director, InVivo Pharmacology, GemPharmatech

12:45 - 13:15

Lunch and Poster Presentation | One-to-One Networking Meetings

13:15 - 14:15

Boosting Cancer Therapy in immunotherapy with next microbiome generation co-cultured product

Nathalie Corvaia

Nathalie Corvaia, Chief Scientific Officer, MaaT Pharma

15:15 - 15:45

NEW ANTOBODY FORMATS AND TUMOR MICRO-ENVIROMENT

Gamma delta T cells as cancer immunotherapeutics

Jonathan Fisher

Jonathan Fisher, T-Cell Immunotherapy, Group Leader, University College London

14:15 - 14:45

A novel redirecting antibody targeting SCLC

Lindy Durrant

Lindy Durrant, Professor, Cancer Immunotherapy, CEO, ScanCell Ltd

14:45 - 15:15

Afternoon Refreshments and Poster Presentation | One-to-One Networking Meetings

15:45 - 16:30

Tumour micro environment and CAR-T Cell Therapy

Etienne De Braekeleer

Etienne De Braekeleer, Senior Scientist - Cell Biology & Research Immunology, AstraZeneca

16:30 - 17:00

iPSC derived cell therapies for the treatment of cancer

Michael Epstein

Michael Epstein, VP, Head of Translational Research in Innovate Oncology , Evotec

17:00 - 17:30

Closing Remarks from the Chairperson

17:30 - 17:30

Registration

08:15 - 08:50

Welcome note from MarketsandMarkets

08:50 - 08:55

Opening Remarks from the Chairperson

08:55 - 09:00

CAR-T CELL THERAPY DEVELOPMENTS AND UPDATES

Keynote Presentation- CAR T-cell immunotherapy of solid tumours: moving through the generations

John Maher

John Maher, Scientific Founder and Chief Scientific Officer, Leucid Bio

09:00 - 09:30

A novel Neuropilin-1 (NRP1) antisense oligonucleotide (ASO) with strong in vivo antitumor activity as single agent and in combination with immune checkpoint inhibitors

Konstantin Petropoulos

Konstantin Petropoulos, Chief Business Officer, Secarna Pharmaceuticals

09:30 - 10:00

Nu.Q® Discover – Quantitative nucleosome biomarker profiling of the tumour microenvironment

Mark Eccleston

Mark Eccleston, Chief Technology Officer, Volition

10:00 - 10:30

Morning Refreshments and Poster Presentation | One-to-One Networking Meetings

10:30 - 11:15

Precise spatial multiplexing with ChipCytometry: An open-source solution to high-throughput spatial biology

Anders Eriksson

Anders Eriksson, Lead Field Application Scientist , Canopy Biosciences

11:15 - 11:45

Programmable and autoregulated viral vectors for new applications of gene therapy

Farzin Farzaneh

Farzin Farzaneh, CSO, ViroCell Biologics Ltd

11:45 - 12:15

....

Joanna Brewer

Joanna Brewer, Chief Scientific Officer, Adaptimmune

12:15 - 12:45

T cell mechanostimulation as a promising approach for enhancing immunotherapies

Sebastian Lickert

Sebastian Lickert, Group Lead, ETH Zürich

12:45 - 13:15

Lunch and Poster Presentation | One-to-One Networking Meetings

13:15 - 14:15

NEW CHECKPOINTS FOR IO-PERSONALIZED IMMUNOTHERAPY

Enhanced Biomarker Discovery and Validation Using TMT® Proteomics

Ian Pike

Ian Pike, Chief Scientific Officer, Proteome Sciences PLC

14:15 - 14:45

Monocytes and Macrophages in Ovarian Cancer, Biomarker and therapeutic Opportunities in their Overlooked immune Checkpoints

Fernando Oneissi Martinez Estrada

Fernando Oneissi Martinez Estrada, Senior Lecturer in Innate Immunology, University of Surrey

14:45 - 15:15

New class of Antigen-specific Cancer Active Immunotherapies based on an off-the-shelf Antigen Presenting Cell line (PDC*line)

Eric Halioua

Eric Halioua, President & CEO, PDC*line Pharma

15:15 - 15:45

Afternoon Refreshments and Poster Presentation | One-to-One Networking Meetings

15:45 - 16:30

...

Phillip Brailey

Phillip Brailey, Senior Scientist, Crescendo Biologics

16:30 - 17:00

Oncolytic viruses in the era of Checkpoint Blockade

17:00 - 17:30

Closing Remarks from the Chairperson

17:30 - 17:30

Registration

08:15 - 08:50

Welcome note from MarketsandMarkets

08:50 - 08:55

Opening Remarks from the Chairperson

08:55 - 09:00

FROM BIOMARKERS TO CDx: STRATEGIES TO ACCELERATE CDx DEVELOPMENT AND COMMERCIALIZATION

Keynote Presentation : Use of biomarkers in clinical development to guide dosing regimen recommendation with the use of modelling and simulations models.

Patrick Brossard

Patrick Brossard, Director, Clinical Pharmacology, SOBI - Swedish Orphan Biovitrum AB

09:00 - 09:30

Tracking challenging pharmacodynamic biomarkers in normal tissue on Phase I clinical trials of new oncology agents

Karen Swales

Karen Swales, Senior Scientific Officer, Clinical PD Biomarker Group, The Institute of Cancer Research

09:30 - 10:00

With only 1/500 Biomarkers reaching the patient what can we do better?

Christopher Peters

Christopher Peters, Clinical Senior Lecturer, Imperial College London

10:00 - 10:30

Morning Refreshments and Poster Presentation | One-to-One Networking Meetings

10:30 - 11:15

CLINICAL APPLICATIONS OF BIOMARKERS IN IMMUNOLOGY, NEUROLOGY, AND OTHER DISEASES

Anti-CD89 antibody for personalized treatment of IgA-mediated inflammatory disorders: Autoantigen-specific IgA, a biomarker with strong effector functions.

Louis Boon

Louis Boon, CSO , JJP Biologics

11:15 - 11:45

The Lymphocyte Stability Index - a pan-cancer biomarker for response to immune checkpoint blockade

Robert Watson

Robert Watson, Clinical Lecturer, University of Oxford

11:45 - 12:15

Histone based liquid biopsies for the screening of cancer and cardiovascular diseases

Manlio Vinciguerra

Manlio Vinciguerra, European Research Area (ERA) Chair, Medical University Varna & Faculty , Liverpool John Moores University, Liverpool

12:15 - 12:45

Generating pseudo-time progression of mucosal inflammation during Inflammatory Bowel Disease using spatially resolved multi-omics data

Priyank Patel

Priyank Patel, Senior Scientist, Department of Immunology & Respiratory Discovery Research, Boehringer Ingelheim Pharmaceuticals, Inc

12:45 - 13:15

Lunch and Poster Presentation | One-to-One Networking Meetings

13:15 - 14:15

Panel Discussion: Moderator : What are the biggest challenges faced in developing an assay: why and what have we learnt from it ?

Patrick Brossard

Patrick Brossard, Director, Clinical Pharmacology, SOBI - Swedish Orphan Biovitrum AB

Christopher Peters

Christopher Peters, Clinical Senior Lecturer, Imperial College London

Maria Dermit

Maria Dermit, Computational Biologist, Novo Nordisk Research Centre Oxford

Manlio Vinciguerra

Manlio Vinciguerra, European Research Area (ERA) Chair, Medical University Varna & Faculty , Liverpool John Moores University, Liverpool

Fernando Oneissi Martinez Estrada

Fernando Oneissi Martinez Estrada, Senior Lecturer in Innate Immunology, University of Surrey

14:15 - 14:45

Closing Remarks from the Chairperson

14:45 - 14:50

END OF CONFERENCE

14:50 - 14:50

Registration

08:15 - 08:50

Welcome note from MarketsandMarkets

08:50 - 08:55

Opening Remarks from the Chairperson

08:55 - 09:00

PRE-CLINICAL AND TRANSLATIONAL IO DEVELOPMENTS-PERSONALIZED CANCER IMMUNOTHERAPY

Keynote Presentation: Cross Training technology: augmenting cross-presentation of neo-antigens

Raj Mehta

Raj Mehta, Founder, Chief Executive Officer & Director, Adendra Therapeutics

09:00 - 09:30

Personalized Immunotherapies: Past, Present and Future

Elizabeth Sheppard

Elizabeth Sheppard, Global Pricing & Market Access Director, Oncology Diagnostics,, AstraZeneca

09:30 - 10:00

Unlocking IL-2 therapeutic power using Attenukine™ platform

Iris Hecht

Iris Hecht, Sr. Director, Project Leader, Specialty Projects, Teva

10:00 - 10:30

Morning Refreshments and Poster Presentation | One-to-One Networking Meetings

10:30 - 11:15

LATEST DEVELOPMENTS & TRENDS IN IO RESEARCH

Generative AI designed Personalized Neoantigen Vaccines

Daniela Kleine-Kohlbrecher

Daniela Kleine-Kohlbrecher, Senior Project Manager Immune Oncology, Evaxion Biotech

11:15 - 11:45

Exploring γδT Reprogramming as a Solution for Donor Material Access and Donor-to-Donor Variability

Daria Paruzina

Daria Paruzina, Senior Manager of Product Development and Platform Expansion, TC BioPharm

11:45 - 12:15

Cross Training technology: augmenting cross-presentation of neo-antigens

Raj Mehta

Raj Mehta, Founder, Chief Executive Officer & Director, Adendra Therapeutics

12:15 - 12:45

Cancer Vaccines: bringing safety and specificity to immunotherapy

John Maudsley

John Maudsley, CEO, Cancer Vaccines Ltd

12:45 - 13:15

Lunch and Poster Presentation | One-to-One Networking Meetings

13:15 - 14:15

Panel Discussion: Immunotherapy Frontiers: Integrating Precision Immunology, Cancer Microbiome, and CAR-T Therapies for Tailored Patient Care

John Maher

John Maher, Scientific Founder and Chief Scientific Officer, Leucid Bio

John Maudsley

John Maudsley, CEO, Cancer Vaccines Ltd

Elizabeth Sheppard

Elizabeth Sheppard, Global Pricing & Market Access Director, Oncology Diagnostics,, AstraZeneca

Louis Boon

Louis Boon, CSO , JJP Biologics

14:15 - 14:45

Closing Remarks from the Chairperson

14:45 - 14:50

SPEAKERS

Angela Vasaturo

Angela Vasaturo

Senior Field Application Scientist , Ultivue, UK

Aparna Duggirala

Aparna Duggirala

Lecturer, Clinical Genetics, University of Derby

Emmanuel Valentin

Emmanuel Valentin

Vice President, Translational Medicine, Imcheck Therapeutics

Farzin Farzaneh

Farzin Farzaneh

CSO, ViroCell Biologics Ltd

Daniel Royston

Daniel Royston

Consultant Clinical Advisor, Ground Truth Labs

Maria Dermit

Maria Dermit

Computational Biologist, Novo Nordisk Research Centre Oxford

Stephen Beers

Stephen Beers

Professor, Immunology and Immunotherapy, University of Southampton

Senior Representative, Canopy Biosciences

Senior Representative, Canopy Biosciences

,

Konstantin Petropoulos

Konstantin Petropoulos

Chief Business Officer, Secarna Pharmaceuticals

Senior Representative, Gempharmatech

Senior Representative, Gempharmatech

Senior Representative,, Gempharmatech

Sebastian Lickert

Sebastian Lickert

Group Lead, ETH Zürich

Christopher Peters

Christopher Peters

Clinical Senior Lecturer, Imperial College London

Georges Rawadi

Georges Rawadi

CEO, Celyad Oncology

Jonathan Fisher

Jonathan Fisher

T-Cell Immunotherapy, Group Leader, University College London

Sreejith Raveendran

Sreejith Raveendran

Assistant Professor, Teesside University

Pedro Correa de Sampaio

Pedro Correa de Sampaio

Co-Founder, CEO,, Neobe Therapeutics

Andrew Sewell

Andrew Sewell

Distinguished Research Professor and Wellcome Trust Senior Investigator,, Cardiff University

Phillip Brailey

Phillip Brailey

Senior Scientist, Crescendo Biologics

Karen Swales

Karen Swales

Senior Scientific Officer, Clinical PD Biomarker Group, The Institute of Cancer Research

Senior Representative Volition

Senior Representative Volition

,

Daria Paruzina

Daria Paruzina

Senior Manager of Product Development and Platform Expansion, TC BioPharm

Paola Giunti

Paola Giunti

Professorial Research Associate, UCL

Collin Hidzik

Collin Hidzik

Scientist in product and business development , EpigenDx

Eric Halioua

Eric Halioua

President & CEO, PDC*line Pharma

Raj Mehta

Raj Mehta

Founder, Chief Executive Officer & Director, Adendra Therapeutics

Ian Pike

Ian Pike

Chief Scientific Officer, Proteome Sciences PLC

Jianming Xu

Jianming Xu

Director, InVivo Pharmacology, GemPharmatech

Michael Epstein

Michael Epstein

VP, Head of Translational Research in Innovate Oncology , Evotec

Joanna Brewer

Joanna Brewer

Chief Scientific Officer, Adaptimmune

Louis Boon

Louis Boon

CSO , JJP Biologics

Anil Thotakura

Anil Thotakura

Head of Immuno-Oncology, Orion Pharmaceuticals

Anne-Sophie Pailhes-Jimenez

Anne-Sophie Pailhes-Jimenez

R&D Director, ANGLE Europe Limited

Sophia Karagiannis

Sophia Karagiannis

Professor, Translational Cancer Immunology and Immunotherapy, Kings College London, UK

Senior Representative, Ground Truth Labs

Senior Representative, Ground Truth Labs

Senior Representative, Ground Truth Labs

Ali Roghanian

Ali Roghanian

PhD, FHEA | Associate Prof in Cancer Immunotherapy | BM Research Project Deputy Module Leader, Centre for Cancer Immunology | Faculty of Medicine | University of Southampton

Eike Staub

Eike Staub

Head, Oncology Bioinformatics, Merck Healthcare, Germany

Nathalie Steinhoff

Nathalie Steinhoff

Scientist, Cancer Immunotherapy, Numab Therapeutics AG

Robert Watson

Robert Watson

Clinical Lecturer, University of Oxford

Etienne De Braekeleer

Etienne De Braekeleer

Senior Scientist - Cell Biology & Research Immunology, AstraZeneca

Debora Souza Da Costa

Debora Souza Da Costa

Senior Biosample Project Leader., Roche

Valerie Balme

Valerie Balme

Associate Director, Business Development, Biopharma

John Maher

John Maher

Scientific Founder and Chief Scientific Officer, Leucid Bio

Nathalie Corvaia

Nathalie Corvaia

Chief Scientific Officer, MaaT Pharma

Elizabeth Sheppard

Elizabeth Sheppard

Global Pricing & Market Access Director, Oncology Diagnostics,, AstraZeneca

Christian Garde

Christian Garde

Scientific Director, Bioinformatics, Evaxion Biotech A/S

John Maudsley

John Maudsley

CEO, Cancer Vaccines Ltd

Iris Hecht

Iris Hecht

Sr. Director, Project Leader, Specialty Projects, Teva

Anders Eriksson

Anders Eriksson

Lead Field Application Scientist , Canopy Biosciences

ENQUIRE NOW

SPONSORS

LOCATION

Venue

Park Plaza Victoria London by Radisson, 239 Vauxhall Bridge Rd, Pimlico, London SW1V 1EQ, UK

PAST EVENT GALLERY